Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
110M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
250K
-
Shares change
-
+189K
-
Total reported value, excl. options
-
$805K
-
Value change
-
+$608K
-
Number of buys
-
16
-
Price
-
$3.22
Significant Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q4 2022
17 filings reported holding ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share as of Q4 2022.
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 250K shares
of 110M outstanding shares and own 0.23% of the company stock.
Largest 10 shareholders include Cypress Point Wealth Management, LLC (94.4K shares), CI Private Wealth, LLC (61.2K shares), VANGUARD GROUP INC (29.1K shares), BlackRock Inc. (23.1K shares), RENAISSANCE TECHNOLOGIES LLC (17.5K shares), GEODE CAPITAL MANAGEMENT, LLC (14K shares), BALDWIN BROTHERS LLC/MA (9.19K shares), MORGAN STANLEY (1.36K shares), CREDIT SUISSE AG/ (120 shares), and Carmichael Hill & Associates, Inc. (75 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.